Welcome to our dedicated page for DICE Therapeutics news (Ticker: DICE), a resource for investors and traders seeking the latest updates and insights on DICE Therapeutics stock.
DICE Therapeutics, Inc. (NASDAQ: DICE) is a distinguished biopharmaceutical company renowned for leveraging its proprietary DELSCAPE technology platform to develop groundbreaking oral therapeutic candidates. Founded with a vision to revolutionize chronic disease treatment in the realm of immunology, DICE is dedicated to creating advanced oral treatments for autoimmune and inflammatory conditions.
The company's core technology, DELSCAPE, is designed to discover selective oral small molecules that can modulate protein-protein interactions (PPIs) as effectively as systemic biologics. This innovation is aimed at providing patients with convenient oral alternatives to traditional injectable therapies. DICE's lead therapeutic candidates include oral antagonists for the pro-inflammatory signaling molecule IL-17, which is a validated drug target implicated in a variety of immunological disorders.
DICE's notable projects include the development of oral IL-17 inhibitors such as DC-806 and DC-853, currently in clinical development, aimed at treating conditions like psoriasis and other autoimmune diseases. Additionally, the company is advancing oral therapeutic candidates targeting the integrin α4β7 for the treatment of inflammatory bowel disease, showcasing its commitment to addressing significant unmet medical needs.
In a strategic move to bolster its capabilities and market presence, DICE recently entered into a definitive agreement to be acquired by Eli Lilly and Company (NYSE: LLY) for approximately $2.4 billion. This acquisition underscores the potential and value of DICE's innovative approaches and proprietary technology. Eli Lilly's extensive resources and global reach are expected to enhance the development and commercialization of DICE's therapeutic pipeline, accelerating the availability of these transformative treatments to patients worldwide.
Financially, the acquisition represents a premium of about 40% to DICE's 30-day volume-weighted average trading price, reflecting strong market confidence in DICE's future prospects. The transaction, approved by the boards of directors of both companies, is anticipated to close in the third quarter of 2023, pending customary closing conditions and regulatory approvals.
With a team of dedicated experts and a robust pipeline of oral therapeutics, DICE Therapeutics stands at the forefront of innovation in immunology, poised to make significant strides in improving patient outcomes for chronic and debilitating diseases.
DICE Therapeutics, a biopharmaceutical company traded on Nasdaq under the symbol DICE, announced its participation in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference, scheduled for March 30, 2023, at 4:00 p.m. ET. The event will focus on DICE's novel oral therapeutic candidates targeting chronic diseases in immunology, utilizing its proprietary DELSCAPE technology platform. A live and archived webcast will be available for 90 days post-event on the company's website. DICE is dedicated to developing effective oral treatments against key immunology targets like IL-17 and integrin α4ß7, aiming to match systemic biologics' potency.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced significant advancements in its clinical pipeline, highlighted by the FDA's clearance of the IND application for its lead oral IL-17 antagonist, DC-806. A global Phase 2b trial for DC-806 in psoriasis is set to begin in 1H 2023. Additionally, the company has initiated a Phase 1 trial for its second oral IL-17 antagonist, DC-853, with topline data expected in 2H 2023. As of December 31, 2022, DICE reported a robust cash position of $574.2 million, projected to fund operations through 2026 and important clinical milestones.
DICE Therapeutics, Inc. (Nasdaq: DICE) announced that data from its Phase 1 clinical trial of DC-806 will be presented at the 2023 American Academy of Dermatology Annual Meeting on March 18, 2023. DC-806 is a small molecule antagonist targeting IL-17, which plays a crucial role in psoriasis. This presentation aims to showcase the proof-of-concept findings for treating mild-to-moderate psoriasis. DICE plans to advance DC-806 into a Phase 2b clinical trial in the first half of 2023, following positive Phase 1 results. The company focuses on developing oral therapeutics for chronic conditions, including psoriasis, inflammatory bowel disease, and idiopathic pulmonary fibrosis.
DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company specializing in oral therapeutics for chronic diseases, announced participation in two major investor conferences. The SVB Securities Global Biopharma Conference features a fireside chat on February 14, 2023, at 2:20 p.m. ET, followed by the 43rd Annual Cowen Healthcare Conference dermatology panel on March 7, 2023, at 12:50 p.m. ET. Live and archived webcasts of these presentations will be available for 90 days on the company’s website. DICE focuses on developing novel oral candidates targeting immunology, aiming for comparable effectiveness to existing biologics.
FAQ
What is the market cap of DICE Therapeutics (DICE)?
What does DICE Therapeutics, Inc. specialize in?
What is DELSCAPE technology?
What are DICE's lead therapeutic candidates?
Who is acquiring DICE Therapeutics, Inc.?
What will be the impact of the acquisition by Eli Lilly?
What chronic diseases is DICE focusing on?
How does DICE's technology benefit patients?
What financial terms were agreed upon for the acquisition?
What are the expected closing conditions for the acquisition?
Where can I find more information about DICE's clinical developments?
